Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan

Wu-Chou Su, Tsai-Yun Chen, Ruey Ho Kao, Chao Jung Tsao

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Twenty-five patients with metastatic and/or recurrent nasopharyngeal car-cinoma were treated with cisplatin 20 mg/m2/day on days 1-5 i.v. with hydra-tion; 5-fluorouracil (5-FU) 1, 000 mg/m2/day by continuous infusion (CI); and bleomycin 15 mg/m2 on day 1 also by CI. These cycles were repeated every 4 weeks. Twenty-three (92%) had distant metastases. Bone was the most fre-quently involved site (72%), followed by lungs (44%) and liver (40%). More than half the patients (14/25) presented with at least 3 organ sites involved or had local T3/T4 or N3 lesions with a distant metastasis. The median time from relapse to start of chemotherapy was 7.5 months. We observed 1 (4%) complete response (CR), and 9 (36%) partial responses (PR). The objective response rate (CR + PR) was 40%. Hematologic toxicities were frequently encountered. Twenty (80%) patients experienced leukopenia during the treatment courses and 9 (36%) had severe (grade 3 or 4) leukopenia. Eight patients had grade 3 or 4 infections. Two of them died of sepsis and 1 succumbed to uncontrolled pneumonia. The objective response rate was inferior to other series. Possible explanation included longer delay before initiation of definitive treatment, larger tumor burdens, higher severe hematologic toxicity and lower dosage of bleomycin. The results suggested metastatic and/or recurrent nasopharyngeal carcinoma is chemosensitive, however, for patients with large tumor burdens, more intensive chemotherapy regimens with support of hematopoietic growth factors may be required to achieve a better control.

Original languageEnglish
Pages (from-to)205-208
Number of pages4
JournalOncology (Switzerland)
Volume50
Issue number4
DOIs
Publication statusPublished - 1993 Jan 1

Fingerprint

Bleomycin
Taiwan
Fluorouracil
Cisplatin
Drug Therapy
Leukopenia
Tumor Burden
Hydra
Neoplasm Metastasis
Sepsis
Intercellular Signaling Peptides and Proteins
Pneumonia
Nasopharyngeal carcinoma
Bone and Bones
Recurrence
Lung
Liver
Therapeutics
Infection

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{9edd5cac371948a4befbf5dc6d7d0021,
title = "Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan",
abstract = "Twenty-five patients with metastatic and/or recurrent nasopharyngeal car-cinoma were treated with cisplatin 20 mg/m2/day on days 1-5 i.v. with hydra-tion; 5-fluorouracil (5-FU) 1, 000 mg/m2/day by continuous infusion (CI); and bleomycin 15 mg/m2 on day 1 also by CI. These cycles were repeated every 4 weeks. Twenty-three (92{\%}) had distant metastases. Bone was the most fre-quently involved site (72{\%}), followed by lungs (44{\%}) and liver (40{\%}). More than half the patients (14/25) presented with at least 3 organ sites involved or had local T3/T4 or N3 lesions with a distant metastasis. The median time from relapse to start of chemotherapy was 7.5 months. We observed 1 (4{\%}) complete response (CR), and 9 (36{\%}) partial responses (PR). The objective response rate (CR + PR) was 40{\%}. Hematologic toxicities were frequently encountered. Twenty (80{\%}) patients experienced leukopenia during the treatment courses and 9 (36{\%}) had severe (grade 3 or 4) leukopenia. Eight patients had grade 3 or 4 infections. Two of them died of sepsis and 1 succumbed to uncontrolled pneumonia. The objective response rate was inferior to other series. Possible explanation included longer delay before initiation of definitive treatment, larger tumor burdens, higher severe hematologic toxicity and lower dosage of bleomycin. The results suggested metastatic and/or recurrent nasopharyngeal carcinoma is chemosensitive, however, for patients with large tumor burdens, more intensive chemotherapy regimens with support of hematopoietic growth factors may be required to achieve a better control.",
author = "Wu-Chou Su and Tsai-Yun Chen and Kao, {Ruey Ho} and Tsao, {Chao Jung}",
year = "1993",
month = "1",
day = "1",
doi = "10.1159/000227179",
language = "English",
volume = "50",
pages = "205--208",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "4",

}

Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan. / Su, Wu-Chou; Chen, Tsai-Yun; Kao, Ruey Ho; Tsao, Chao Jung.

In: Oncology (Switzerland), Vol. 50, No. 4, 01.01.1993, p. 205-208.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan

AU - Su, Wu-Chou

AU - Chen, Tsai-Yun

AU - Kao, Ruey Ho

AU - Tsao, Chao Jung

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Twenty-five patients with metastatic and/or recurrent nasopharyngeal car-cinoma were treated with cisplatin 20 mg/m2/day on days 1-5 i.v. with hydra-tion; 5-fluorouracil (5-FU) 1, 000 mg/m2/day by continuous infusion (CI); and bleomycin 15 mg/m2 on day 1 also by CI. These cycles were repeated every 4 weeks. Twenty-three (92%) had distant metastases. Bone was the most fre-quently involved site (72%), followed by lungs (44%) and liver (40%). More than half the patients (14/25) presented with at least 3 organ sites involved or had local T3/T4 or N3 lesions with a distant metastasis. The median time from relapse to start of chemotherapy was 7.5 months. We observed 1 (4%) complete response (CR), and 9 (36%) partial responses (PR). The objective response rate (CR + PR) was 40%. Hematologic toxicities were frequently encountered. Twenty (80%) patients experienced leukopenia during the treatment courses and 9 (36%) had severe (grade 3 or 4) leukopenia. Eight patients had grade 3 or 4 infections. Two of them died of sepsis and 1 succumbed to uncontrolled pneumonia. The objective response rate was inferior to other series. Possible explanation included longer delay before initiation of definitive treatment, larger tumor burdens, higher severe hematologic toxicity and lower dosage of bleomycin. The results suggested metastatic and/or recurrent nasopharyngeal carcinoma is chemosensitive, however, for patients with large tumor burdens, more intensive chemotherapy regimens with support of hematopoietic growth factors may be required to achieve a better control.

AB - Twenty-five patients with metastatic and/or recurrent nasopharyngeal car-cinoma were treated with cisplatin 20 mg/m2/day on days 1-5 i.v. with hydra-tion; 5-fluorouracil (5-FU) 1, 000 mg/m2/day by continuous infusion (CI); and bleomycin 15 mg/m2 on day 1 also by CI. These cycles were repeated every 4 weeks. Twenty-three (92%) had distant metastases. Bone was the most fre-quently involved site (72%), followed by lungs (44%) and liver (40%). More than half the patients (14/25) presented with at least 3 organ sites involved or had local T3/T4 or N3 lesions with a distant metastasis. The median time from relapse to start of chemotherapy was 7.5 months. We observed 1 (4%) complete response (CR), and 9 (36%) partial responses (PR). The objective response rate (CR + PR) was 40%. Hematologic toxicities were frequently encountered. Twenty (80%) patients experienced leukopenia during the treatment courses and 9 (36%) had severe (grade 3 or 4) leukopenia. Eight patients had grade 3 or 4 infections. Two of them died of sepsis and 1 succumbed to uncontrolled pneumonia. The objective response rate was inferior to other series. Possible explanation included longer delay before initiation of definitive treatment, larger tumor burdens, higher severe hematologic toxicity and lower dosage of bleomycin. The results suggested metastatic and/or recurrent nasopharyngeal carcinoma is chemosensitive, however, for patients with large tumor burdens, more intensive chemotherapy regimens with support of hematopoietic growth factors may be required to achieve a better control.

UR - http://www.scopus.com/inward/record.url?scp=0027210488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027210488&partnerID=8YFLogxK

U2 - 10.1159/000227179

DO - 10.1159/000227179

M3 - Article

VL - 50

SP - 205

EP - 208

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -